Oral Presentations

Estimation of human papillomavirus (HPV) transmissibility: insights from mathematical modeling EUROGIN 2013 HPV AT A CROSSROADS - 30 YEARS OF RESEARCH AND PRACTICE. Florence, Italy. November 3-6, 2013. Brisson M
HPV vaccination in developing countries: assessing the value of vaccines across the world EUROGIN 2013 HPV AT A CROSSROADS - 30 YEARS OF RESEARCH AND PRACTICE. Florence, Italy. November 3-6, 2013. Jit M, Brisson M, Portnoy A, Hutubessy R
2 vs. 3 doses Schedule - High income countries (HIC) EUROGIN 2013 HPV AT A CROSSROADS - 30 YEARS OF RESEARCH AND PRACTICE. Florence, Italy. November 3-6, 2013. Brisson M
Inequalities in cervical cancer: role of vaccine herd immunity in protecting women with low screening participation EUROGIN 2013 HPV AT A CROSSROADS - 30 YEARS OF RESEARCH AND PRACTICE. Florence, Italy. November 3-6, 2013. Malagon T, Drolet M, Boily MC, Laprise JF, Brisson M
Cross-protection and alternating doses schedules EUROGIN 2013 HPV AT A CROSSROADS - 30 YEARS OF RESEARCH AND PRACTICE. Florence, Italy. November 3-6, 2013. Brisson M
Comparing the cost-effectiveness of the bivalent, quadrivalent and nonavalent HPV vaccines: a model-based analysis 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Brisson M, Van de Velde N, Laprise JF, Drolet M, Boily MC
Incremental cost-effectiveness of vaccinating boys against human papillomavirus (HPV) in Canada: a model-based analysis 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Laprise JF, Van de Velde N, Boily MC, Drolet M, Brisson M
Examining the potential population-level impact of maldistribution of HPV vaccine by future cervical screening participation 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Malagon T, Van de Velde N, Boily MC, Laprise JF, Drolet M, Brisson M
Vaccinating girls with the bivalent and boys with the quadrivalent vaccine: Is it a good idea? 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Drolet M, Van de Velde N, Boily MC, Brisson M
Prevalence of Heterosexual Anal Intercourse Among sexually Active Youth: A Systematic Review and Meta-analysis 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Boily MC, Owen B, Baggaley RF, Butler AR, Pickles M, Brisson M, Drolet M
Estimating the Long-Term Impact and Cost-Effectiveness of Prophylactic Human Papillomavirus Vaccination in Medically Underserved, Low Income Populations in the United States 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Ekwueme DU, Geng Y, Chesson HW, Cooney D, Saraiya M, Brisson M, Franco EL, Li C, Benard V, Royalty J, Watson M
Can we have two instead of three? –Mathematical modelling effects of two dose HPV vaccine schedules 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Choi YH, Brisson M, Boily MC, Van de Velde N, Laprise JF, Jit M
What’s it worth? Cost-Effectiveness of Vaccinating Males Against HPV 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Brisson M
Understanding the public health consequences of the epidemiological interaction between HIV and HPV infections 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012 Boily MC, Looker KJ, Brisson M, Drolet M
Systematic review of oral HPV infection risk factors 28th International Papillomavirus Conference. San Juan, Puerto Rico. November 30- December 6, 2012. Lemieux-Mellouki P, Drolet M, Boily MC, Brisson M
Serotype replacement : Should we be worried? EUROGIN Congress 2012. Prague, Czech Republic. July 8-11, 2012. Boily MC, Van de Velde N, Brisson M
Cross-protection: How do we interpret trial data, and how important is it at a population-level? EUROGIN 2012 Congress. Prague, Czech Republic. July 8-11, 2012. Malagòn T, Van de Velde N, Drolet M, Laprise JF, Boily MC, Brisson M
The Impact of vaccination on HPV-related diseases in men & women: A Model-based analysis EUROGIN 2012 Congress. Prague, Czech Republic. July 8-11, 2012. Brisson M, Van de Velde N, Drolet M, Laprise JF, Malagòn T, Boily MC
Cost-effectiveness issues - are they questionable? EUROGIN Congress 2012. Prague, Czech Republic. July 8-11, 2012 Brisson M
Population-level effectiveness and cost-effectiveness of HPV vaccination strategies: A comparative model-based analysis Center for Disease Control. Atlanta, Georgia, United States. February 2, 2012. Brisson M
Sociodemographic inequalities in the main risk factors for HPV-related diseases 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Drolet M, Brisson M
HPV– vaccine programs: when can we know we are reaching objectives? 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Boily MC, Van de Velde N, Drolet M, Laprise JF, Malagon T, Brisson M
Modeling the effectiveness of the bivalent, quadrivalent and nonavalent vaccines 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Van de Velde N, Malagon T, Drolet M, Laprise JF, Boily MC, Brisson M
Role of mathematical models to monitor and evaluate HPV vaccination 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Boily MC, Brisson M
Impact of cross-protection: from clinical trial results to population-level effectiveness 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Brisson M, Van de Velde N, Malagon T, Drolet M, Laprise JF, Boily MC
HPV transmissibility and HPV-status at partnership separation: a model-based analysis 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Laprise JF, Van de Velde N, Boily MC, Drolet M, Brisson M
Issues in comparing and interpreting clinical trial measures of cross-protection 27th International papillomavirus conference. Berlin, Germany. September 17- 23, 2011. Malagon T, Drolet M, Van de Velde N, Boily MC, Brisson M
Vaccination des garçons contre le Virus du papillome humain (VPH): état des connaissances Public Health Conference. Université Laval, Quebec, Canada. September 11, 2011. Brisson M
Potential impact of HPV vaccination on health disparities EUROGIN 2011 Congress. Lisbon, Portugal. May 8- 11, 2011. Brisson M, Van de Velde N, Boily MC
Examining the potential impact of HPV vaccination on health disparities using mathematical models SIMID workshop. Antwerp, Belgium. January 31- February 1, 2011. Brisson M, Van de Velde N, Boily MC
Understanding the psychosocial burden of genital warts in Canada: A prospective 6-month study 26th International papillomavirus conference. Montreal, Canada. July 3- 4, 2010. Drolet M, Brisson M, Maunsell E, Ferenczy A, Franco E, Coutlée F, Palefsky J, Mansi J
Impact of disparities in HPV vaccine coverage on population-level effectiveness 26th International papillomavirus conference. Montréal, Canada. July 3-8, 2010 Brisson M, Van de Velde N, Boily MC
Predictors of high anxiety following an abnormal cervical cytology result 26th International papillomavirus conference. Montreal ,Canada. July 3- 4, 2010. Drolet M, Brisson M, Maunsell E, Ferenczy A, Franco E, Coutlée F, Palefsky J, Mansi J
Smaller population-level impact of HPV vaccines on HPV-16/18 compared to HPV-6/11: what are the implications 26th International papillomavirus conference. Montreal, Canada. July 3- 4, 2010. Boily MC, Van de Velde N, Brisson M
Smaller population-level impact of HPV vaccines on HPV-16/18 compared to HPV-6/11: what are the implications Montréal, Canada. July 3-8, 2010 Boily MC, Van de Velde N, Brisson M
Modeling the incremental impact of vaccinating boys against HPV 26th International papillomavirus conference. Montréal, Canada. July 3-8, 2010 Brisson M, Van de Velde N, Boily MC
Disparities in Gardasil uptake in Manitoba, Canada prior to the implementation of an immunization program 26th International papillomavirus conference. Montreal, Canada. July 3- 4, 2010. Kliewer E, Demers A, Lambert P, Brisson M
Impact of structural uncertainty on predictions of HPV vaccine effectiveness: A comparative model-based analysis SIMID workshop. Antwerp, Belgium. April 12- 14, 2010. Brisson M, Van de Velde N, Boily MC
Cost-effectiveness of 1- and 2-dose varicella vaccination SIMID workshop. Antwerp, Belgium. April 12- 14, 2010. Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P
The ABC of Cost-Effectiveness and Economic Evaluation of HPV Vaccination Toronto Health Economics and Technology Assessment Collaborative. University of Toronto, Toronto, Canada. March 12, 2010. Brisson M
Loss of quality of life associated with genital warts: a prospective 6-month study EUROGIN 2010 Congress. Monte Carlo, Monaco. February 17- 20, 2010 Drolet M, Brisson M, Maunsell , Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Blanchette C, Mansi JA
Modelling the impact of vaccinating males against HPV infection. EUROGIN 2010 Congress Monte Carlo, Monaco. February 17- 20, 2010 Brisson M, Van de Velde N, Boily MC
Modelling the herd-immunity impact of female vaccination on HPV infection in males EUROGIN 2010 Congress. Monte Carlo, Monaco. February 17- 20, 2010 Brisson M, Van de Velde N, Boily MC
Quality of life lost following an abnormal cervical cytology result: a prospective 3-month study EUROGIN 2010 Congress. Monte Carlo, Monaco. February 17- 20, 2010 Brisson M, Drolet M, Maunsell , Ferenczy A, Franco EL, Ratnam S, Coutlée F, Palefsky JM, Blanchette C, Mansi JA
Quality of life EUROGIN 2010 Congress. Monte Carlo, Monaco. February 17- 20, 2010. Brisson M
The Cost of Treating Anogenital Warts in Manitoba, Canada 24th International papillomavirus conference. Beijing, China. November 2- 10, 2007. Butler JRG, Kliewer EV, Demers AA, Musto G, Lotocki R, Elliott L, Brisson M
Dynamic modeling of HPV vaccine effectiveness: Impact of uncertainty in biological and behavioural parameter assumptions and model structure 18th ISSTDR Conference, London, UK. June 28-July 1st 2009 Van de Velde N, Brisson M, Boily MC
Dynamic modeling of HPV vaccine effectiveness: Impact of partnership formation 25th International papillomavirus conference, Malmo, Sweden. May 8-14, 2009 Van de Velde N, Brisson M, Boily MC
Dynamic modeling of HPV vaccine effectiveness: Impact of structure 25th International papillomavirus conference. Malmo, Sweden. May 8- 14, 2009. Van de Velde N, Brisson M, Boily MC
Modeling the impact of a second dose of varicella vaccination on varicella and herpes zoster Global Virology Foundation conference. Annecy, France. April 18, 2009. Brisson M
Effects of vaccines - Chickenpox vaccination on chickenpox and herpes zoster Global Virology Foundation conference. Annecy, France. May 18, 2009. Brisson M
QALY-lost during the first 90 days after the onset of Herpes Zoster 8th Canadian Immunization Conference, Toronto, Canada. November 30-December 3, 2008 Drolet M, Brisson M, Johnson RW, Levin MJ, Oxman MN, Schmader KE, Patrick DM, Mansi JA
Potential Cost-effectiveness of vaccination against Herpes Zoster and PHN in Canada 7th Canadian Immunization Conference, Winnipeg, Canada. December 3-6, 2006 Brisson M, Pellissier JM, Quach C, De Wals P
The Health and Economic Burden of HPV Infection, Dysplasia and Cervical Cancer in Canada 7th Canadian Immunization Conference, Winnipeg, Canada. December 3-6, 2006 Brisson M, Van de Velde N, Boily MC, De Wals P
Measuring the Pain and Severity Associated with the Prodromal Phase of Herpes Zoster (HZ) in Canada: A Prospective Community Based Study 13th Annual Meeting of the International Herpes Management Forum (IHMF), Prague, Czech Republic. October 27-29, 2006 Brisson M, Johnson RW, Levin MJ, Oxman MN, Schmader KE, Patrick DM, Koch C, Senecal M, Mansi JA
Measuring the Pain and Severity Associated with the Prodromal Phase of Herpes Zoster (HZ) in Canada: A Prospective Community Based Study 7th Canadian Immunization Conference, Winnipeg, Canada. December 3-6, 2006 risson M, Johnson RW, Levin MJ, Oxman MN, Schmader KE, Patrick DM, Koch C, Senecal M, Mansi JA
Evaluation of the cost-effectiveness in the U.S. of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults National Foundation for Infectious Diseases Vaccine Research 9th Annual Conference, Baltimore, Maryland. May 8-10, 2006 Pellissier JM, Brisson M, Levin MJ
Potential Cost-effectiveness of vaccination against Herpes Zoster and PHN in Canada 44th Annual Meeting of the Infectious Diseases Society of America (IDSA), Toronto, Canada. October 12-15, 2006 Brisson M, Pellissier JM, Quach C, De Wals P
Login

Admin panel